Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Molecular Reproduction and Development|April 5, 2002
Expression of glutamate-cysteine ligase during mouse developmentDolores Díaz, Cecile M Krejsa, Terrance J Kavanagh
Analytical Biochemistry|June 20, 2003
Fluorescence-based microtiter plate assay for glutamate-cysteine ligase activityCollin C White, Hannah Viernes, Cecile M Krejsa, et al.
Reproductive Toxicology (Elmsford, N.Y.)|September 1, 2004
Effect of methylmercury on glutamate-cysteine ligase expression in the placenta and yolk sac during mouse developmentDolores Díaz, Cecile M Krejsa, Collin C White, et al.
The American Journal of Pathology|May 10, 2002
Caspase-3-Dependent Cleavage of the Glutamate-L-Cysteine Ligase Catalytic Subunit during Apoptotic Cell DeathChristopher C Franklin, Cecile M Krejsa, Robert H Pierce, et al.
Current Opinion in Drug Discovery & Development|September 4, 2003
Predicting ADME properties and side effects: the BioPrint approachCecile M Krejsa, Dragos Horvath, Sherri L Rogalski, et al.
The Journal of Biological Chemistry|March 25, 2010
Rapid activation of glutamate cysteine ligase following oxidative stressCecile M Krejsa, Christopher C Franklin, Collin C White, et al.
Journal of Immunotoxicology|February 7, 2013
An inter-laboratory retrospective analysis of immunotoxicological endpoints in non-human primates: flow cytometry immunophenotypingCecile M Krejsa, Moni Blazej Neradilek, Nayak L Polissar, et al.
Free Radical Biology & Medicine|August 4, 2004
Glutamate-cysteine ligase attenuates TNF-induced mitochondrial injury and apoptosisDianne Botta, Christopher C Franklin, Collin C White, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 4, 2020
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or AcalabrutinibJim S Qin, Timothy G Johnstone, Alex Baturevych, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|July 16, 2019
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juicesXavier J H Pepin, Andrea J Moir, James C Mann, et al.
Pageof 2